Genetic testing

Inocras Pioneers Precision Health with Revolutionary Whole Genome Insights

Retrieved on: 
Thursday, April 25, 2024
Oncology, Data Management, Health, Technology, Genetics, Artificial Intelligence, Biotechnology, Cancer, Sequence, Genetic testing, Disease, Patient, Genome, Diagnosis, Whole genome sequencing, Genetic counseling

Inocras, a leading AI-driven whole genome testing company, proudly announces the launch of CancerVision and RareVision, its flagship whole genome diagnostics solutions in solid tumor cancer and rare disease, respectively.

Key Points: 
  • Inocras, a leading AI-driven whole genome testing company, proudly announces the launch of CancerVision and RareVision, its flagship whole genome diagnostics solutions in solid tumor cancer and rare disease, respectively.
  • The clinical use of whole genome sequencing has relatively been limited due to cost and technology barriers.
  • “This milestone solidifies our position as the whole-genome precision health leader.”
    Inocras Inc. (formerly Genome Insight, Inc) is a pioneering provider of whole genome sequencing and analytics services for cancer and rare diseases.
  • The company is dedicated to unlocking the potential of genomic data to enable precision health for everyone.

Parkinson’s Foundation and Tasso Announce Partnership to Accelerate Parkinson’s Disease Genetics Research

Retrieved on: 
Tuesday, April 23, 2024
Data Management, Technology, Health, Philanthropy, Seniors, Neurology, Health Technology, Infectious Diseases, Genetics, Foundation, Consumer, Science, Parkinson's disease, GP2, Partnership, Collection, Doctor of Philosophy, Research, Coalition, Genetic testing, Disease, Senior, Patient, Physician, Data collection, ASAP, Multimedia, PD, Genetic counseling, Gene, Pharmaceutical industry

The Parkinson’s Foundation and Tasso, Inc. today announced a partnership to expand and accelerate genetic research into Parkinson’s disease (PD).

Key Points: 
  • The Parkinson’s Foundation and Tasso, Inc. today announced a partnership to expand and accelerate genetic research into Parkinson’s disease (PD).
  • The partnership leverages Tasso’s patient-centric, end-to-end sample collection and logistics platform to enable data collection for a landmark international genetics study by the Parkinson’s Foundation: PD GENEration: Mapping the Future of Parkinson’s .
  • The goal of the research is to screen the collected samples for mutations among select, clinically relevant PD genes.
  • “Tasso and the Parkinson’s Foundation share a mission to accelerate life-changing research,” said Ben Casavant, PhD, CEO and co-founder of Tasso.

Reproductive Medicine Associates Network Top Ranked in Newsweek’s ‘America’s Best Fertility Clinics’

Retrieved on: 
Monday, April 22, 2024
Women, Baby, Maternity, Genetics, LGBTQ+, Men, Family, Other Health, Health, Consumer, Infertility, Fertility, Research, Genetic testing, IVF, Newsweek, Embryo, ART, RMA, Reproductive medicine, Professional, Basking Ridge, New Jersey, Patient, IUI, Ovulation, Reproductive endocrinology and infertility, Birth control

Reproductive Medicine Associates (RMA), one of the nation's leading reproductive service providers and a pioneer in IVF research, today announced that four clinics in its network were ranked in Newsweek’s 2024 list of America’s Best Fertility Clinics .

Key Points: 
  • Reproductive Medicine Associates (RMA), one of the nation's leading reproductive service providers and a pioneer in IVF research, today announced that four clinics in its network were ranked in Newsweek’s 2024 list of America’s Best Fertility Clinics .
  • RMA Basking Ridge , was ranked the 11th best fertility clinic in the country.
  • RMA King of Prussia , Conceptions Reproductive Associates of Colorado , and RMA Seattle also ranked among the top 125 U.S. fertility clinics.
  • “We are honored that several of our facilities, including our Basking Ridge headquarters, ranked among the top fertility clinics in the country,” said Lynn Mason, CEO.

Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications

Retrieved on: 
Monday, April 22, 2024
Research, Genetics, Clinical Trials, Biotechnology, Other Health, Health, Other Science, Science, Oncology, Nucleic acid thermodynamics, NTRA, Investment, Publication, Colorectal cancer, Genetic testing, SMART, DNA, NIPT, Patient, Kidney transplantation, NEJM, Clinical trial, ProActive, Chronic kidney disease, Cohort (statistics), Pharmaceutical industry

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that it has passed a significant milestone with the publication of more than 200 peer-reviewed papers highlighting Natera’s technology in the scientific literature.

Key Points: 
  • Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that it has passed a significant milestone with the publication of more than 200 peer-reviewed papers highlighting Natera’s technology in the scientific literature.
  • Landmark cutting-edge science and clinical trial data based on Natera’s suite of products have been published in top journals, such as Science, Nature, Nature Medicine, and New England Journal of Medicine (NEJM).
  • “When it comes to transforming patient care, high-quality science and data drive everything,” said Alexey Aleshin, M.D., chief medical officer & general manager of oncology at Natera.
  • We remain committed to generating evidence that supports the real-world impact of our innovations.”

Executive War College to Address, Clinical Laboratories’ and Genetic Testing Firms’ Perfect Storm, involving FDA’s Proposed LDT Rule, Payers Requiring Z-Codes on Genetic Test Claims, and Revisions to CLIA Regulations

Retrieved on: 
Friday, April 19, 2024
FDA, Health Technology, Publishing, Healthcare Reform, Communications, General Health, Medical Devices, Public Policy, Government, Genetics, Clinical Trials, Science, Biotechnology, Other Science, Health, Research, Dark, Storm, Organization, COLA, Leica Biosystems, Laboratory, Food, CDC, Cleveland Clinic, DLS, MD, Clinical Laboratory, Doctor of Philosophy, ISO, Pathology, Artificial intelligence, History, Genetic testing, ARUP Laboratories, CLIA, Marie Cassidy, Medical device, College, Multimedia, French Quarter, Division, IVD, Darkness

One is the Food and Drug Administration’s (FDA) proposed rule https://www.fda.gov/news-events/press-announcements/fda-proposes-rule-ai... to regulate laboratory developed tests (LDTs).

Key Points: 

United States In-Vitro Diagnostics Market Insights 2024-2029: Increasing Adoption Of Automation in Laboratories and Growing Importance of IVD In Healthcare Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, April 15, 2024
Genetics, Health, Oncology, Other Health, USD, Cancer, Pandemic, Automation, Risk, Thermo Fisher Scientific, Bio-Rad Laboratories, Hospital, Hematology, Siemens Healthineers, Diabetes, Calibration, Genetic testing, Infection, Documentation, 2005 in television, Diagnosis, COVID-19, IVD, Growth, Liquid biopsy, Medical device

The leading market players in the US IVD market are F Hoffmann-La Roche, Abbott, Thermo Fisher Scientific, Diasorin, Biomerieux, Danaher, Bio-Rad, and Siemens Healthineers, competing with rapidly emerging market players.

Key Points: 
  • The leading market players in the US IVD market are F Hoffmann-La Roche, Abbott, Thermo Fisher Scientific, Diasorin, Biomerieux, Danaher, Bio-Rad, and Siemens Healthineers, competing with rapidly emerging market players.
  • Vendors in the market are increasing their market share through inorganic growth strategies.
  • The reagents and consumables product segment occupies a major market share of over 67% in the U.S. in-vitro diagnostics (IVDs) market.
  • What is the growth rate of the U.S. in-vitro diagnostics (IVDs) market?

Global Fertility Services Market Insights and Forecasts, 2020-2023, 2024 and 2025-2030 with Analyst Recommendations and Profiles of Key Players - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 11, 2024
Parenting, Health, Consumer, Other Health, Medication, Diagnosis, Pregnancy, Policy, Infertility, SWOT analysis, Fertility, Uterus, IVF, Tubing (recreation), Disease, ART, STI, Poverty, Reproductive technology, Movement, Research, Failure, Unsafe abortion, Da Vinci Surgical System, Endocrine system, Channel, LMIC, Genetic testing, Birth control

The "Global Fertility Services Market (2024 Edition): Analysis By Gender (Male, Female), Treatment Type, Channel, Services , By Region, By Country: Market Insights and Forecast (2020-2030)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Fertility Services Market (2024 Edition): Analysis By Gender (Male, Female), Treatment Type, Channel, Services , By Region, By Country: Market Insights and Forecast (2020-2030)" report has been added to ResearchAndMarkets.com's offering.
  • The report presents the analysis of Fertility Services Market for the historical period of 2020-2023, the estimated year 2024 and the forecast period of 2025-2030.
  • The report also studies the Fertility Services Market By Channel (Fertility Clinics, Hospitals, Research Institutes, and Others) and By Services (IVF, Genetic Testing, and Reproductive Tissue Storage and Donor Services).
  • Also, the attractiveness of the market has been presented by region, By Gender, By Treatment Type, By Channel, & By Services.

Prevent Blindness Declares May as First-ever Inherited Retinal Disease (IRD) Genetic Testing Awareness Month

Retrieved on: 
Wednesday, April 24, 2024
Education, Paratriathlon, University, Blood, Birth defect, Retina, RP, Social media, Diagnosis, Stargardt disease, Stargardt, Marketing, Strabismus, Genetic, Johnson & Johnson, Gene, Spark Therapeutics, Choroid, Research, Visual impairment, Genetic testing, Pediatric ophthalmology, Disease, Visual Science, Patient, Eye, Cone dystrophy, MBA, Vision, Student, Therapy, Organization, IRD, Pharmaceutical industry

CHICAGO, April 24, 2024 /PRNewswire-PRWeb/ -- Prevent Blindness, the nation's leading nonprofit eye health and safety organization, has designated May as "Inherited Retinal Disease (IRD) Genetic Testing Awareness Month," expanding its previous IRD and Genetic Testing Awareness Week initiative. The group is providing a variety of tools to promote awareness and education for IRDs and the importance of genetic testing, including a free webinar, expert and patient videos, shareable social media graphics, and fact sheets in English and Spanish. IRD Genetic Testing Awareness Month is supported by funding from Johnson & Johnson, and Spark® Therapeutics.

Key Points: 
  • Prevent Blindness expands IRD and genetic testing awareness initiative to educate patients on various forms of IRDs, and the importance of genetic testing to confirm diagnosis and possible treatments.
  • CHICAGO, April 24, 2024 /PRNewswire-PRWeb/ -- Prevent Blindness , the nation's leading nonprofit eye health and safety organization, has designated May as "Inherited Retinal Disease (IRD) Genetic Testing Awareness Month," expanding its previous IRD and Genetic Testing Awareness Week initiative.
  • ET, the National Center for Children's Vision and Eye Health at Prevent Blindness will be hosting the free webinar, " Pathway to Diagnosis: Genetic Testing for Inherited Retinal Diseases ."
  • To register for the "Pathway to Diagnosis: Genetic Testing for Inherited Retinal Diseases" webinar, visit PreventBlindness.org/IRD-webinar-2024.

GenEmbryomics and Progenesis Announce Strategic Partnership to Transform IVF Testing

Retrieved on: 
Wednesday, April 24, 2024
DSM-IV codes, Genomics, PGT, Infertility, ICSI, Partnership, Fertility, Parent, Science, Genetic testing, IVF, Patient, Diagnosis, MBA, Whole genome sequencing, Reproductive medicine

Through this partnership, GenEmbryomics and Progenesis will join forces to offer the powerful benefits of preimplantation genetic testing with whole genome sequencing (PGT-WGS) to fertility patients.

Key Points: 
  • Through this partnership, GenEmbryomics and Progenesis will join forces to offer the powerful benefits of preimplantation genetic testing with whole genome sequencing (PGT-WGS) to fertility patients.
  • Progenesis will leverage its state-of-the-art laboratory and facilities, while GenEmbryomics will serve as the preferred provider of its Panacea-GenomeScreen™ PGT-WGS test, the first and only comprehensive PGT-WGS embryo genetic test.
  • "Partnering with GenEmbryomics marks a pivotal step in our unwavering commitment to providing the premier IVF testing service," said Nabil Arrach, Ph.D., MBA, CEO of Progenesis.
  • "We are ecstatic to partner with Progenesis, a leader in IVF whose track-record in making IVF testing available to everyone speaks for itself," said Nick Murphy, Ph.D., Managing Director of GenEmbryomics.

Introducing Rare Parenting: The Online Publication for Parents of Children with Special Needs

Retrieved on: 
Tuesday, April 23, 2024
Seizure, Child, Diagnosis, Parenting, Advertising, Nursing, Family, DSM-IV codes, Parent, Movement, Genetic testing, Disability, FOXG1, Residential care

NEW YORK, April 23, 2024 /PRNewswire/ -- Rare Parenting, the online publication providing medically-backed advice for parents of children with disabilities, rare diseases, and special needs announces its official launch. Articles cover topics related to parenting children with special needs, including managing symptoms and surgeries, family and relationships, finances, and self-care. The publication was founded by former advertising and media executive Megan Nolan and was inspired by her personal struggle managing care for her three-year-old son diagnosed with FOXG1 Syndrome.

Key Points: 
  • NEW YORK, April 23, 2024 /PRNewswire/ -- Rare Parenting, the online publication providing medically-backed advice for parents of children with disabilities, rare diseases, and special needs announces its official launch.
  • Articles cover topics related to parenting children with special needs, including managing symptoms and surgeries, family and relationships, finances, and self-care.
  • "Rare Parenting exists to help lift the burden off the shoulders of parents who are struggling alone.
  • Parents should have access to information covering all aspects from diagnosis to caring for a child with special needs.